LifeVantage Announces Preliminary Second Quarter Revenue Results and Raises Fiscal 2025 Revenue Guidance
LifeVantage (Nasdaq: LFVN), a health and wellness company, announced its preliminary second-quarter revenue results for the fiscal year ending December 31, 2024. The company reported revenue of approximately $67.5 million, representing a 31% increase from the same period the previous year and a 43% sequential rise from the first fiscal quarter.
Active Account growth in the Americas saw a 22.7% increase year-over-year and a 25.4% rise sequentially. Globally, Active Accounts grew by 12.1% year-over-year and 18.5% sequentially.
LifeVantage also raised its fiscal 2025 revenue guidance to a range of $235 million to $245 million, up from the previously expected $200 million to $210 million. The company attributes this growth to the strong sales of the MindBody GLP-1 System™ launched in October in the United States, as well as exceptional execution in ramping up supply chain and fulfillment capacities to meet demand.
CEO Steve Fife highlighted the highest number of enrollments in a quarter since Q3 of fiscal 2019, indicating strong business momentum and a positive outlook for continued growth and shareholder value. Detailed profitability outlook will be provided in early February when the company reports its full fiscal Q2 results.
LifeVantage (Nasdaq: LFVN), una società di salute e benessere, ha annunciato i risultati preliminari delle entrate del secondo trimestre per l'anno fiscale che termina il 31 dicembre 2024. L'azienda ha riportato entrate di circa 67,5 milioni di dollari, con un aumento del 31% rispetto allo stesso periodo dell'anno precedente e un incremento del 43% rispetto al primo trimestre fiscale.
La crescita degli account attivi nelle Americhe ha visto un aumento del 22,7% su base annua e un incremento del 25,4% rispetto al trimestre precedente. A livello globale, gli account attivi sono aumentati del 12,1% rispetto all'anno precedente e del 18,5% rispetto al trimestre precedente.
LifeVantage ha anche rivisto al rialzo le previsioni di entrate per l'anno fiscale 2025, portandole a un intervallo di 235 milioni a 245 milioni di dollari, rispetto ai precedenti 200 milioni a 210 milioni di dollari. L'azienda attribuisce questa crescita alle forti vendite del sistema MindBody GLP-1™ lanciato a ottobre negli Stati Uniti, oltre a un'eccellente esecuzione nell'aumento delle capacità della catena di approvvigionamento e di evasione degli ordini per soddisfare la domanda.
Il CEO Steve Fife ha evidenziato il numero più alto di iscrizioni in un trimestre dal terzo trimestre dell'anno fiscale 2019, indicando un forte slancio aziendale e un outlook positivo per una continua crescita e valore per gli azionisti. Una valutazione dettagliata della redditività sarà fornita all'inizio di febbraio, quando l'azienda riporterà i risultati completi del secondo trimestre fiscale.
LifeVantage (Nasdaq: LFVN), una empresa de salud y bienestar, anunció sus resultados preliminares de ingresos del segundo trimestre para el año fiscal que finaliza el 31 de diciembre de 2024. La compañía reportó ingresos de aproximadamente 67,5 millones de dólares, lo que representa un aumento del 31% en comparación con el mismo período del año anterior y un incremento del 43% respecto al primer trimestre fiscal.
El crecimiento de las cuentas activas en las Américas tuvo un aumento del 22,7% interanual y un incremento del 25,4% secuencial. A nivel global, las cuentas activas crecieron un 12,1% en comparación con el año anterior y un 18,5% secuencialmente.
LifeVantage también elevó su guía de ingresos para el año fiscal 2025 a un rango de 235 millones a 245 millones de dólares, en comparación con los 200 millones a 210 millones de dólares previamente esperados. La empresa atribuye este crecimiento a las fuertes ventas del Sistema MindBody GLP-1™ lanzado en octubre en los Estados Unidos, así como a una ejecución excepcional para aumentar la capacidad de la cadena de suministro y de cumplimiento para satisfacer la demanda.
El CEO Steve Fife destacó el mayor número de inscripciones en un trimestre desde el tercer trimestre del año fiscal 2019, indicando un fuerte impulso empresarial y una perspectiva positiva para un crecimiento continuo y valor para los accionistas. Se proporcionará un pronóstico detallado de rentabilidad a principios de febrero cuando la empresa informe sus resultados completos del segundo trimestre fiscal.
LifeVantage (Nasdaq: LFVN), 건강 및 웰빙 회사가 2024년도 12월 31일 종료되는 회계연도의 2분기 예상 수익 결과를 발표했습니다. 회사는 약 6,750만 달러의 수익을 보고했으며, 이는 작년 같은 기간에 비해 31% 증가한 수치이며, 1분기 대비로는 43% 증가한 수치입니다.
미주 지역의 활성 계정 성장률은 전년 대비 22.7% 증가하였으며, 이전 분기 대비로는 25.4% 증가했습니다. 전 세계적으로 활성 계정은 전년 대비 12.1% 증가하였고, 이전 분기 대비로는 18.5% 증가했습니다.
LifeVantage는 또한 2025년도 회계연도 수익 안내를 2억 3,500만 달러에서 2억 4,500만 달러로 상향 조정했으며, 이는 당초 예상했던 2억에서 2억 1,000만 달러에서 증가한 것입니다. 회사는 이러한 성장을 미국에서 10월에 출시된 MindBody GLP-1 시스템™의 강력한 판매와, 수요 충족을 위한 공급망 및 이행 능력 향상을 통한 탁월한 실행에 기인한다고 보고했습니다.
CEO 스티브 피프는 2019 회계연도 3분기 이후 가장 많은 분기 등록 수를 강조하며, 강력한 사업 동향과 지속적인 성장 및 주주 가치를 위한 긍정적인 전망을 나타냈습니다. 세부적인 수익성 전망은 회사가 2분기 전체 결과를 발표하는 2월 초에 제공될 예정입니다.
LifeVantage (Nasdaq: LFVN), une entreprise de santé et de bien-être, a annoncé ses résultats préliminaires de revenus pour le deuxième trimestre de l'exercice se terminant le 31 décembre 2024. La société a déclaré un revenu d'environ 67,5 millions de dollars, représentant une augmentation de 31 % par rapport à la même période l'année précédente et une hausse de 43 % par rapport au premier trimestre de l'exercice.
La croissance des comptes actifs en Amérique a enregistré une augmentation de 22,7 % par rapport à l'année précédente et une hausse de 25,4 % par rapport au trimestre précédent. À l'échelle mondiale, les comptes actifs ont augmenté de 12,1 % par rapport à l'année précédente et de 18,5 % par rapport au trimestre précédent.
LifeVantage a également relevé ses prévisions de revenus pour l'exercice 2025 dans une fourchette de 235 millions à 245 millions de dollars, contre les précédentes prévisions de 200 millions à 210 millions de dollars. L'entreprise attribue cette croissance aux ventes solides du système MindBody GLP-1™ lancé en octobre aux États-Unis, ainsi qu'à une exécution exceptionnelle dans l'augmentation des capacités de la chaîne d'approvisionnement et d'exécution pour répondre à la demande.
Le PDG Steve Fife a souligné le plus grand nombre d'inscriptions dans un trimestre depuis le troisième trimestre de l'exercice 2019, ce qui indique une forte dynamique d'affaires et une perspective positive pour une croissance continue et une valeur pour les actionnaires. Une perspective de rentabilité détaillée sera fournie début février lorsque l'entreprise annoncera ses résultats complets du deuxième trimestre.
LifeVantage (Nasdaq: LFVN), ein Unternehmen für Gesundheit und Wellness, hat seine vorläufigen Umsatzresultate für das zweite Quartal des zum 31. Dezember 2024 endenden Geschäftsjahres bekannt gegeben. Das Unternehmen berichtete von einem Umsatz von etwa 67,5 Millionen Dollar, was einem Anstieg von 31 % im Vergleich zum Vorjahreszeitraum und einem sequentiellen Anstieg von 43 % gegenüber dem ersten Geschäftsjahr entspricht.
Das Wachstum aktiver Konten in Amerika verzeichnete einen Anstieg von 22,7 % im Jahresvergleich und einen Anstieg von 25,4 % im Vergleich zum vorherigen Quartal. Weltweit wuchsen die aktiven Konten um 12,1 % im Jahresvergleich und um 18,5 % sequentiell.
LifeVantage hat auch seine Umsatzprognose für das Geschäftsjahr 2025 auf einen Bereich von 235 Millionen bis 245 Millionen Dollar angehoben, im Vergleich zu den zuvor erwarteten 200 Millionen bis 210 Millionen Dollar. Das Unternehmen führt dieses Wachstum auf die starken Verkäufe des im Oktober in den Vereinigten Staaten eingeführten MindBody GLP-1-Systems™ sowie auf eine außergewöhnliche Umsetzung zur Steigerung der Lieferketten- und Erfüllungskapazitäten zur Deckung der Nachfrage zurück.
CEO Steve Fife hob die höchste Anzahl von Einschreibungen in einem Quartal seit dem dritten Quartal des Geschäftsjahres 2019 hervor, was auf einen starken Geschäftsmomentum und eine positive Aussicht für anhaltendes Wachstum und Wert für die Aktionäre hinweist. Eine detaillierte Rentabilitätsprognose wird Anfang Februar bereitgestellt, wenn das Unternehmen seine vollständigen Ergebnisse für das zweite Geschäftsjahr vorlegt.
- Revenue of approximately $67.5 million, a 31% increase year-over-year.
- Sequential revenue growth of 43% from the first fiscal quarter.
- Active Account growth in the Americas up 22.7% year-over-year.
- Global Active Account growth up 12.1% year-over-year.
- Raised fiscal 2025 revenue guidance to $235 million to $245 million, up from $200 million to $210 million.
- None.
Insights
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced preliminary revenue results for the second quarter ended December 31, 2024, and raised its fiscal 2025 revenue guidance.
Preliminary Second Quarter Fiscal 2025 Highlights:
- Revenue of approximately
$67.5 million , an increase of31% from the prior year period, and up43% sequentially from the first fiscal quarter - Active Account growth in the Americas of
22.7% in comparison to the prior year period, and up25.4% sequentially from the first fiscal quarter - Active Account growth of
12.1% globally in comparison to the prior year period, and up18.5% sequentially from the first fiscal quarter
Fiscal 2025 Guidance:
- The Company now expects revenue in the range of
$235 million to$245 million in fiscal 2025 compared to prior revenue guidance of$200 million to$210 million
“Second quarter revenue results were exceptional, reflecting strong sales of the MindBody GLP-1 System™ we launched in October in the United States along with outstanding execution by our team to quickly ramp supply chain and fulfillment capacity to meet the robust demand,” said Steve Fife, President and CEO of LifeVantage. “We also saw significant growth in Active Accounts driven by the highest number of enrollments in a quarter since third quarter of fiscal 2019. We look forward to providing more details, including our profitability outlook, when we report our fiscal Q2 results in early February. With business momentum strong, we remain well positioned to deliver significant growth and shareholder value.”
About LifeVantage Corporation
LifeVantage Corporation® (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System™, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own sales business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements we make regarding expected financial performance, including financial guidance and projections relating to expected revenue and margins, expected demand from our independent Consultants and Customers, executing against and the benefits of our key initiatives, and expected future growth and expansion, including geographic and product expansion. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, our ability to properly motivate and incentivize sales from our independent Consultants, our ability to retain existing Customers and independent Consultants or attract additional Customers and independent Consultants, our dependence on a few products for a majority of our revenue, our dependency on third parties to manufacture our products, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
FAQ
What were LifeVantage's preliminary Q2 revenue results for fiscal 2025?
How much did LifeVantage's revenue increase year-over-year in Q2 fiscal 2025?
What is LifeVantage's new revenue guidance for fiscal 2025?
What was the sequential revenue growth for LifeVantage in Q2 fiscal 2025?
How much did Active Accounts grow in the Americas for LifeVantage in Q2 fiscal 2025?
What was the global Active Account growth for LifeVantage in Q2 fiscal 2025?
What contributed to LifeVantage's revenue growth in Q2 fiscal 2025?
When will LifeVantage report its full fiscal Q2 results?
